The management strategy of pancreatic cancer in the era of systemic therapy-"Surgery First" or "Surgery Last"?
作者信息
Yang Yinmo, Tian Xiaodong
机构信息
Department of General Surgery, Peking University First Hospital, Beijing, China.
出版信息
Hepatobiliary Surg Nutr. 2022 Aug;11(4):597-600. doi: 10.21037/hbsn-22-146.
Abstract
摘要
相似文献
1
The management strategy of pancreatic cancer in the era of systemic therapy-"Surgery First" or "Surgery Last"?全身治疗时代胰腺癌的管理策略——“手术优先”还是“手术最后”？
Hepatobiliary Surg Nutr. 2022 Aug;11(4):597-600. doi: 10.21037/hbsn-22-146.
2
Multimodality Therapy in Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Importance of Locoregional Therapies for a Systemic Disease.可切除边缘或局部晚期胰腺癌患者的多模态治疗：局部区域治疗对全身性疾病的重要性
J Oncol Pract. 2016 Oct;12(10):915-923. doi: 10.1200/JOP.2016.016162.
3
Is Surgery-first Still a Reasonable Option in the Era of Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer?新辅助化疗时代可切除胰腺癌中手术优先是否仍然合理？
Am J Clin Oncol. 2020 Apr;43(4):298-304. doi: 10.1097/COC.0000000000000661.
4
Preoperative therapies for resectable and borderline resectable pancreatic cancer.可切除和交界可切除胰腺癌的术前治疗。
J Gastrointest Oncol. 2011 Sep;2(3):136-42. doi: 10.3978/j.issn.2078-6891.2011.030.
5
Advances in neoadjuvant therapy for resectable pancreatic cancer over the past two decades.过去二十年中可切除胰腺癌新辅助治疗的进展。
Ann Hepatobiliary Pancreat Surg. 2021 May 31;25(2):179-191. doi: 10.14701/ahbps.2021.25.2.179.
6
Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?新辅助治疗在胰腺癌治疗中的作用：生物标志物指导治疗时代是否已经到来？
Curr Oncol. 2014 Aug;21(4):e650-7. doi: 10.3747/co.21.2006.
7
Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014: Relevance of Surgical Cure in the Era of Modern Systemic Therapy.1965 年至 2014 年腹部内脏型黑色素瘤转移患者的手术治疗、系统治疗与生存的相关性：现代系统治疗时代手术治愈的相关性。
JAMA Surg. 2017 Jul 1;152(7):672-678. doi: 10.1001/jamasurg.2017.0459.
8
Survival after Margin-Positive Resection in the Era of Modern Chemotherapy for Pancreatic Cancer: Do Patients Still Benefit?在现代胰腺癌化疗时代，边缘阳性切除术后的生存：患者仍受益吗？
J Am Coll Surg. 2021 Jul;233(1):100-109. doi: 10.1016/j.jamcollsurg.2021.02.020. Epub 2021 Mar 26.
9
Clinical Limitations of Photon, Proton and Carbon Ion Therapy for Pancreatic Cancer.胰腺癌的光子、质子和碳离子治疗的临床局限性
Cancers (Basel). 2020 Jan 9;12(1):163. doi: 10.3390/cancers12010163.
10
Robotic treatment of oligometastatic kidney tumor with synchronous pancreatic metastasis: case report and review of the literature.机器人辅助治疗寡转移肾肿瘤合并同步胰腺转移：病例报告及文献复习
BMC Surg. 2018 Jun 13;18(1):40. doi: 10.1186/s12893-018-0371-x.
引用本文的文献
1
Prognostic significance of grade of malignancy based on histopathological differentiation and Ki-67 in pancreatic ductal adenocarcinoma.基于组织病理学分化和 Ki-67 评估胰腺导管腺癌恶性程度分级的预后意义。
Cancer Biol Med. 2024 Jan 3;21(5):416-32. doi: 10.20892/j.issn.2095-3941.2023.0363.
本文引用的文献
1
Molecular characterization of circulating tumor cells in pancreatic ductal adenocarcinoma: potential diagnostic and prognostic significance in clinical practice.胰腺导管腺癌循环肿瘤细胞的分子特征：临床实践中的潜在诊断和预后意义。
Hepatobiliary Surg Nutr. 2021 Dec;10(6):796-810. doi: 10.21037/hbsn-20-383.
2
Does neoadjuvant therapy improve survival in pancreatic adenocarcinoma?新辅助治疗能否提高胰腺腺癌患者的生存率？
Hepatobiliary Surg Nutr. 2021 Oct;10(5):728-730. doi: 10.21037/hbsn-21-250.
3
Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer.可切除及临界可切除胰腺癌的多模式标准治疗护理
Hepatobiliary Surg Nutr. 2021 Oct;10(5):714-716. doi: 10.21037/hbsn-21-131.
4
Predicting early recurrence for resected pancreatic ductal adenocarcinoma: a multicenter retrospective study in China.预测切除术后胰腺导管腺癌的早期复发：一项中国多中心回顾性研究
Am J Cancer Res. 2021 Jun 15;11(6):3055-3069. eCollection 2021.
5
Surgery for pancreatic cancer: recent progress and future directions.胰腺癌手术：近期进展与未来方向
Hepatobiliary Surg Nutr. 2021 Jun;10(3):376-378. doi: 10.21037/hbsn-21-18.
6
Total Neoadjuvant Therapy for Operable Pancreatic Cancer.可切除胰腺癌的全新辅助治疗
Ann Surg Oncol. 2021 Apr;28(4):2246-2256. doi: 10.1245/s10434-020-09149-3. Epub 2020 Sep 30.
7
Current status and future prospect of surgical treatment for pancreatic cancer.胰腺癌外科治疗的现状与未来展望
Hepatobiliary Surg Nutr. 2020 Feb;9(1):89-91. doi: 10.21037/hbsn.2019.12.04.
8
The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.195 个国家和地区 1990-2017 年胰腺癌的全球、区域和国家负担及其可归因危险因素：2017 年全球疾病负担研究的系统分析。
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):934-947. doi: 10.1016/S2468-1253(19)30347-4. Epub 2019 Oct 21.
9
Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.定义和预测 957 例接受胰腺导管腺癌切除患者的早期复发。
Ann Surg. 2019 Jun;269(6):1154-1162. doi: 10.1097/SLA.0000000000002734.
10
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.影响边界性/局部进展期胰腺癌新辅助放化疗后疗效、围手术期结局及生存的因素。
Ann Surg. 2021 Feb 1;273(2):341-349. doi: 10.1097/SLA.0000000000003284.
Zotero 插件